Haichun Huang

Co-Founder, EVP of Antibody Discovery @ NovaRock Biotherapeutics Ltd

About

A highly accomplished scientific leader with more than 25 years of experience in the biological and pharmaceutical industry, specializing in the discovery and development of therapeutic antibodies. Built and led diverse teams that have successfully identified and advanced over 20 therapeutic antibodies into clinical trials, targeting a wide range of disease areas, including oncology, immuno-oncology, cardiovascular conditions, fibrosis, and autoimmune disorders. Notably, played a pivotal role in the development of the groundbreaking anti-PD-1 antibody, Nivolumab, a cornerstone of the therapeutic drug OPDIVO, recognized as one of the most influential biologic drugs in the pharmaceutical market. Additionally, made significant contributions to the discovery and advancement of the anti-CD20 antibody Ofatummab, a crucial molecule of the therapeutic drug ARZERRA. Furthermore, holds the distinction of being a co-inventor of the therapeutic antibody drugs OPDIVO and ARZERRA, and has co-invented over 30 patents related to therapeutic antibodies and their various applications.

Country

United States

City

Trenton

Industry

Biotechnology

Skill

Multi-functional leadership, Functional Screening, Biotechnology Industry, Cell Culture, functional screening, Innovation Technology, Strategic Planning, ELISA, Project Management, Technological Innovation, HTP Antibody Screening Platform , Hybridoma, Team Building, Antibody Generation, Assay Development, Automation, Multi-functional, Technology Evaluation, Team Leadership, Project Leadership

Experience

Co-Founder, EVP of Antibody Discovery

NovaRock Biotherapeutics Ltd

2018 - Present · 8 yrs

New Jersey, United States

Built and led teams in the discovery and development of over 10 therapeutic antibodies, including four that advanced to clinical trials: anti-IL-23p19 (NBL-012), anti-claudin18.2 (NBL-015), anti-TNFR2 (NBL-020), and anti-claudin6/anti-CD137 bispecific antibody (NBL-028).

Director/Associate Director, Biologic Lead Discovery

Bristol-Myers Squibb

2009-8 - 2018-1 · 8 yrs 6 mos

Redwood City, California, United States

Led the successful discovery and development of FDA-approved therapeutic antibodies, including OPDIVO (anti-PD-1) and KESIMPTA and ARZERRA (anti-CD20).

Assistant Director/Senior Manager/Manager

Medarex

1998-3 - 2009-8 · 11 yrs 6 mos

Milpitas, California, United States

Built and led teams in the discovery and development of therapeutic antibodies using human Ig transgenic mice for Medarex and its collaborators/partners. Eighteen antibodies advanced to clinical trials, including the anti-PD-1 antibody Nivolumab and the anti-CD20 antibody Ofatumumab.